1. Report Introduction 2. Congenital Heart Disease Overview 3. Pipeline Therapeutics • An Overview of Pipeline Products for Congenital Heart Disease 4. Comparative Analysis 5. Products in Clinical Stage 5.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities 6. Products in Pre-Clinical and Discovery Stage 6.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities 7. Therapeutic Assessment • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type 8. Inactive Products 8.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities Appendix Report Methodology Consulting Services Disclaimer About DelveInsight

Table 1: Total Products for Congenital Heart Disease Table 2: Products in Clinical Stage Table 3: Products in Non-clinical Stage Table 4: Assessment by Route of Administration Table 5: Assessment by Stage and Route of Administration Table 6: Assessment by Molecule Type Table 7: Assessment by Stage and Molecule Type Table 8: Inactive Products Figure 1: Total Products for Congenital Heart Disease Figure 2: Products in Clinical Stage Figure 3: Products in Non-clinical Stage Figure 4: Assessment by Route of Administration Figure 5: Assessment by Stage and Route of Administration Figure 6: Assessment by Molecule Type Figure 7: Assessment by Stage and Molecule Type Figure 8: Inactive Products

Shanghai iCELL Biotechnology Co AstraZeneca Ethicare GmbH Bristol-Myers Squibb Vertex Pharmaceuticals Incorporated Gilead Sciences Stealth BioTherapeutics Inc. Actelion Bracco Diagnostics Inc Japan Regenerative Medicine Co. Ltd. Edwards Lifesciences Asklepion Pharmaceuticals LG life science Mallinckrodt Mylan Pharmaceuticals & list continues...